Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) has scheduled a conference call for 10th November 2020 at 8:30 AM Eastern Time to announce its 3Q20 financial results.
The conference call will also be webcast live under the investor relations section of the website www.corbuspharma.com
Earnings Expectation
Corbus Pharmaceuticals Holdings, Inc. is reporting third quarter financial results on Tuesday 10th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, CRBP is expected to report 3Q20 loss of $ 0.42 per share from revenue of $ 1.23 million.
For the full year, analysts anticipate top line of $ 5.82 million, while looking forward to loss of $ 1.68 per share bottom line.
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase 3 clinical trial for the treatment of systemic sclerosis and dermatomyositis, and in Phase 2 clinical trial to treat systemic lupus erythematosus and cystic fibrosis. The company also has a license to develop, manufacture, and market CRB-4001, a 2nd generation peripherally-restricted, CB1 inverse agonist, which is in a preclinical stage to treat liver, lung, heart, and kidney fibrotic diseases.
